A burgeoning telehealth startup, MEDVi, heralded by The New York Times as a prime example of an AI-powered venture reaching unicorn status with minimal human oversight, is now entangled in a web of regulatory warnings, allegations of deceptive marketing practices, and multiple class-action lawsuits. The Los Angeles-based firm, founded by entrepreneur Matthew Gallagher, initially captivated attention with its audacious claims of being the "fastest growing company in history," fueled by its aggressive marketing of GLP-1s and other pharmaceuticals. However, a deeper investigation reveals a pattern of questionable practices, including the use of AI-generated personas, misleading product claims, and a complex operational structure that has drawn the ire of federal regulators and consumer advocates alike.
The Genesis of an AI ‘Unicorn’ and Its Grand Unveiling
The narrative surrounding MEDVi began to solidify in early 2024 when OpenAI CEO Sam Altman famously predicted that a single entrepreneur leveraging artificial intelligence could build a billion-dollar business. Matthew Gallagher, through MEDVi, appeared to be making good on that audacious forecast. By April 2, 2026, The New York Times published a prominent profile on MEDVi, positioning it as a poster child for Altman’s vision. The article detailed Gallagher’s reliance on a suite of AI services, including ChatGPT, Claude, Grok, MidJourney, and Runway, to construct the company. With a lean operational team comprising only Gallagher and his brother Elliot as full-time employees, supported by contract engineers and external agencies, MEDVi projected an astounding $1.8 billion in sales for 2026. The Times reported that it was granted access to MEDVi’s financials to corroborate these impressive revenue and profit figures, painting a picture of unprecedented, AI-accelerated success in the digital health sector. Gallagher stated that the core medical and logistical aspects, such as doctor consultations, pharmacy fulfillment, shipping, and compliance, were outsourced to platforms like CareValidate and OpenLoop Health.
MEDVi’s ascent coincided with a dramatic surge in demand for GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), initially developed for diabetes management but gaining immense popularity for their efficacy in weight loss. The global GLP-1 market, valued at approximately $20 billion in 2023, is projected to skyrocket to over $100 billion by the early 2030s, creating a fertile ground for both legitimate innovation and opportunistic ventures. This booming market, coupled with intermittent shortages of branded GLP-1 drugs, paved the way for compounding pharmacies and telehealth platforms like MEDVi to offer what they presented as accessible alternatives.
Regulatory Alarms: The FDA’s Early Warning
Despite the celebratory tone of the New York Times feature, regulatory storm clouds had already gathered. Six weeks prior to the Times profile, on February 20, 2026, the U.S. Food and Drug Administration (FDA) issued a direct warning letter to MEDVi, LLC, citing significant concerns regarding the misbranding of its compounded drugs. The FDA specifically noted that MEDVi’s website, medvi.io, falsely implied that the company itself was the compounder of the semaglutide and tirzepatide it sold. More critically, the agency flagged claims such as "Same active ingredient as Wegovy® and Ozempic®" and "Same active ingredient as Mounjaro® and Zepbound®" as misleading, asserting that they falsely suggested FDA approval or evaluation for MEDVi’s compounded products. The warning explicitly stated that failure to rectify these violations could lead to severe enforcement actions, including product seizure or injunctions, and cautioned that the cited violations were not exhaustive of all potential issues.
In response to these revelations, MEDVi issued a statement on April 8, claiming that the FDA-cited website, medvi.io, belonged to an affiliate marketing agency and that MEDVi itself had "never received a letter from the FDA." However, this assertion was directly contradicted by the warning letter itself, which was formally addressed to "MEDVi, LLC dba MEDVi" at its registered Delaware address, utilized MEDVi’s official email address, and specifically referenced the MEDVi-branded claims found on medvi.io. This discrepancy immediately cast doubt on the company’s transparency and willingness to acknowledge regulatory oversight.
A Digital Mirage: AI Personas and Deceptive Advertising Uncovered
The FDA’s warning was merely the tip of the iceberg. Concurrent investigations by Drug Discovery & Development and Business Insider unearthed a pervasive pattern of apparent AI-generated personas and highly deceptive marketing tactics extending far beyond the issues initially identified by regulators.
On April 3, a review by Drug Discovery & Development of MEDVi’s website, Facebook advertising, and public records revealed numerous instances of fabricated physician personas, some even presented with medical titles. A search of Meta’s Ad Library for "medvi" yielded over 5,000 active advertisements, many operating under these seemingly fake doctor profiles. For example, a Facebook page for "Dr. Robert Whitworth," which sponsored ads for MEDVi’s QUAD erectile dysfunction product, was bizarrely categorized as an "Entertainment website" and listed a non-existent address in Cameron, Montana. Other ads featured names like "Professor Albust Dongledore" and "Dr. Richard Hörzgock," utilizing AI-generated video testimonials that recycled identical scripts across multiple fabricated identities. In several instances, a doctor’s headshot would be displayed on the page, while the accompanying ad featured an entirely unrelated individual delivering a patient testimonial. By April 6, many of these evidently fabricated doctor personas had been quietly removed from the site.
A Business Insider investigation published on the same day corroborated these findings, specifically scrutinizing the historical use of AI-generated doctor profiles in Meta ads for MEDVi, many linked to its extensive affiliate network. Gallagher informed Business Insider that "maybe 30%" of MEDVi’s advertising was conducted through affiliates. BI’s report identified profiles such as "Dr. Matthew Anderson MD" (linked to an Angolan phone number and a gospel musician) and "Dr. Spencer Langford MD" (associated with a clothing store in the Republic of Congo), all exhibiting tell-tale signs of AI generation, including garbled text and Gemini watermarks. Following these inquiries, the number of active Medvi-related ads on Meta platforms significantly dropped from over 5,000 to approximately 2,800.
Earlier investigative work by Futurism in May 2025 had already documented concerning practices on MEDVi’s website, including AI-generated patient photos, deepfaked before-and-after weight loss images (traced to photos that had circulated online for years with AI-swapped faces), and AI-generated Ozempic box imagery containing clear errors. At that time, logos from reputable publications like The New York Times, Bloomberg, and Forbes were displayed, implying editorial coverage that did not yet exist. When Futurism contacted doctors listed on MEDVi’s site, at least one, osteopathic practitioner Tzvi Doron, denied any association with the company and demanded his removal. In his later New York Times profile, Gallagher acknowledged that MEDVi’s initial website had indeed featured AI-generated photos and deepfaked weight-loss images.
Adding to the confusion, MEDVi’s website previously listed two physicians, Dr. Ana Lisa Carr and Dr. Kelly Tenbrink, both associated with Ringside Health, a concierge practice in Florida. MEDVi’s site did not disclose their affiliation with Ringside Health. While Dr. Tenbrink was listed as certified by the American Board of Emergency Medicine, and an ABEM credential page confirmed his certification, the Florida Department of Health practitioner profiles for both physicians stated that neither held specialty board certifications recognized by the Florida board. Significantly, after Drug Discovery & Development sought comment from these physicians, MEDVi removed both Dr. Ana Lisa Carr and Dr. Kelly Tenbrink from its website entirely on April 10.
The Compounding Conundrum and the Narrowing Regulatory Gap
MEDVi’s business model heavily relies on navigating the complex and evolving regulatory landscape surrounding compounded medications, particularly GLP-1s. Federal law generally prohibits compounding pharmacies from making copies of FDA-approved drugs. However, sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit compounding under specific circumstances, notably during drug shortages. This provision became critical during the high demand for branded GLP-1s.
However, the regulatory environment has shifted. The FDA officially declared the tirzepatide injection shortage resolved on December 19, 2024, followed by the resolution of the semaglutide injection shortage on February 21, 2025. This resolution significantly impacts the legal justification for compounding these drugs. Many sellers, including those potentially connected to MEDVi’s network, have since pivoted to marketing "personalized" formulations that incorporate additional ingredients, such as vitamin B-12, arguing that these modified versions are not "essentially a copy" of the approved drugs.
The FDA, however, has pushed back against this interpretation. On April 1, 2026, the agency clarified its stance, stating that a compounded product combining semaglutide with another active ingredient like vitamin B-12 may still be considered "essentially a copy" unless a prescriber documents a patient-specific "significant difference" that justifies the modification. Major pharmaceutical companies have also weighed in, with Eli Lilly issuing a strong warning in March 2026 against the practice of compounding tirzepatide with vitamin B-12, underscoring potential safety and efficacy concerns.
Mounting Legal Challenges: Data Breaches and "Modern-Day Snake Oil"
MEDVi’s rapid expansion, claiming "500,000+ MEDVi patients" on its current homepage, has been accompanied by a surge of legal troubles impacting its operational partners and, by extension, itself. The company promises "unlimited 24/7 support" and "doctor-led plans & coaching," with care purportedly provided by OpenLoop Health clinicians.
OpenLoop Health, a Des Moines, Iowa-based telehealth infrastructure company central to MEDVi’s operations, recently disclosed a major cybersecurity breach. On January 7, 2026, a threat actor successfully infiltrated OpenLoop’s systems, claiming to have exfiltrated records from approximately 1.6 million patients. This sensitive data included names, contact information, dates of birth, and medical information. OpenLoop formally notified the Texas Attorney General in March 2026, confirming at least 68,160 affected individuals in that state alone, and now faces multiple class-action lawsuits stemming from this breach.
Adding to the legal quagmire, a North Carolina consumer filed a class-action complaint in the U.S. District Court for the District of Delaware in November 2025 against OpenLoop Health and compounding pharmacy Triad Rx. The lawsuit, disclosed by Fierce Healthcare, alleges that these firms manufactured and sold what the complaint dramatically characterizes as "modern-day snake oil": compounded oral tirzepatide tablets that possess "no demonstrated mechanism of absorption or efficacy." While MEDVi itself is not named as a defendant in this particular suit, the complaint explicitly states that the plaintiff purchased these pills through MEDVi, which it describes as one of dozens of consumer-facing telehealth storefronts operating within a network managed by OpenLoop.
The scientific basis of the "snake oil" allegation is crucial: tirzepatide is a large peptide molecule highly susceptible to destruction by digestive enzymes before it can reach the bloodstream. The only FDA-approved oral GLP-1, Rybelsus (oral semaglutide), requires a specialized absorption enhancer called SNAC to achieve a mere 1% bioavailability, and even then, it must be taken under stringent conditions. The complaint alleges that the "Meet the incredible doctors we’ve partnered with" presentation, which previously featured physicians like Dr. David Mansour (who appeared in a January 2026 MEDVi press release but is no longer on the site), was part of a broader marketing scheme. The lawsuit brings claims under the Racketeer Influenced and Corrupt Organizations Act (RICO), state consumer protection statutes, and common law fraud, alleging that MEDVi was part of a network of nearly identical telehealth storefronts, each with an OpenLoop patient waiting room, marketing the same questionable product through shared backend infrastructure.
Beyond the "snake oil" claims, MEDVi has faced other legal challenges. The company was served in Siuksta v. MEDVi, LLC, a federal Telephone Consumer Protection Act (TCPA) lawsuit filed in May 2025, but failed to appear, leading to a voluntary dismissal after the court noted the default. More recently, James v. Medvi LLC, a class-action case filed in federal court in California on March 20, 2026, accuses MEDVi of benefiting from affiliate spam. The suit cites an email with the subject line "This might be the easiest way to start Ozempic" sent from a nonsensical email address, which routed to a MEDVi landing page with tracking parameters. Filed under California’s anti-spam law, the lawsuit seeks statutory damages of $1,000 per violating email, with the class potentially numbering at least 100,000 individuals.
Founder’s Defense and Public Backlash
Following the mixed reception of The New York Times piece, Matthew Gallagher has actively used social media to defend MEDVi and its practices. In deleted X posts, he derided detractors as having "low testosterone" and labeling them "Karens of the internet." In a notable exchange, he pushed back against Shutterstock founder Jon Oringer, who had sarcastically proposed a "fake-doctor affiliate-as-a-service platform." Gallagher equated MEDVi’s use of AI-generated physician personas with the common practice of using standard medical stock art in advertising, writing: "The guy who SELLS images of doctors to marketers pretends not to understand marketing. The irony is beautiful," and accompanied his post with a screenshot of a stock-style doctor image.
This aggressive defense, however, stands in stark contrast to MEDVi’s official April 8 statement, which claimed the company had "recently become aware" of ads featuring "potentially AI-generated medical practitioners." By April 3, Gallagher was already publicly mocking critics and equating the fake-doctor imagery with ordinary stock-art marketing, suggesting a deeper and earlier awareness of these practices than his company’s official communication indicated.
On April 3, 2026, Gallagher also posted a longer defense of the white-label telemedicine model on X, framing critics as ignorant of modern business practices: "Watching in realtime as people learn about white label, drop shipping, and affiliate marketing is like seeing cavemen ‘fire bad’." He asserted that "white label telemedicine is a huge benefit with a net positive for humanity," claiming it has driven down prices and made healthcare accessible. He dismissed concerns about offering "life-changing weight loss medication, prescribed by a doctor," as critics viewing it as a "trendy ‘pill mill’."
Reactions on platforms like LinkedIn to MEDVi’s model and Gallagher’s defense have been sharply divided. While some congratulated him on the AI-first execution and lauded potential philanthropic goals, others voiced significant skepticism. An SEO professional questioned whether MEDVi’s reported website traffic could genuinely support its claimed user base and revenue. A digital health founder stated, "Something doesn’t add up," and an accountant suggested an independent audit by a reputable firm. Furthermore, a viral YouTube video titled "billion dollar ai company was built on lies" garnered over a million views within three days, directly addressing the controversy, and several alleged customers posted direct complaints about their experiences with MEDVi.
Drug Discovery & Development reached out to MEDVi, Matthew Gallagher, OpenLoop Health, Dr. Kelly Tenbrink, and Dr. Ana Lisa Carr for comment but did not receive an immediate response. Nicholas Chimicles, lead counsel for the plaintiffs in the class-action lawsuits, declined to comment further on the ongoing litigation but confirmed his firm’s awareness of the recent New York Times profile of MEDVi.
Broader Implications for AI, Telehealth, and Regulation
The MEDVi saga underscores critical challenges at the intersection of rapidly advancing artificial intelligence, the burgeoning telehealth sector, and the imperative for robust regulatory oversight. The ease with which AI can generate convincing but deceptive marketing content, including fake personas and deepfaked testimonials, presents a formidable challenge for regulators like the FDA and FTC, as well as for social media platforms responsible for moderating advertising content.
The use of AI in creating misleading healthcare claims, especially for highly sought-after drugs like GLP-1s, raises profound ethical questions and poses significant risks to public health and consumer trust. The bipartisan coalition of 35 attorneys general, in their December 2025 letter to Meta, highlighted these dangers, stating, "The use of artificial intelligence to fabricate images, spokespeople, and medical claims crosses a line and makes these ads particularly dangerous." Reuters also reported in late 2025 that Meta was "earning a fortune on a deluge of fraudulent ads," projecting one-tenth of its 2024 revenue from "scams and banned goods," indicating a systemic issue that platforms are struggling to contain.
While MEDVi’s website includes a disclaimer at the bottom stating, "Individuals appearing in advertisements may be actors or AI portraying doctors and are not licensed medical professionals," the efficacy of such a disclaimer when juxtaposed with aggressive, misleading advertising campaigns remains highly questionable in the eyes of consumer protection laws. The ongoing lawsuits against MEDVi and its partners are likely to set important precedents regarding accountability for AI-generated deception in healthcare marketing and the responsibilities of telehealth infrastructure providers.
The MEDVi case serves as a stark reminder that while AI offers transformative potential for efficiency and accessibility in various sectors, its application in sensitive areas like healthcare demands rigorous ethical considerations, transparent practices, and vigilant regulatory enforcement to safeguard consumers from potential harm and fraud. The dream of an AI-driven billion-dollar company, as envisioned by Sam Altman, is now facing the harsh reality of regulatory scrutiny and public demand for integrity and accountability.
Leave a Reply